Pharmaceutical Industry News Archive
Get news by email or subscribe to our news feeds.
News Archive for March 2007
March 2, 2007
March 5, 2007
March 6, 2007
- FDA Approves Tekturna for High Blood Pressure
- Shires UK Launch Expands Global Reach of Fosrenol
- A New Approach to Asthma Treatment Approved by Health Canada
- Elsevier Acquires the Beilstein Database, World's Leading Archive of Chemical Data
- Jury Finds in Favor of ETHEX/KV on All Claims Against KV Pharmaceutical and ETHEX Subsidiary
March 7, 2007
- Wyeth and Progenics to Begin Clinical Testing of a New Formulation of Oral Methylnaltrexone Based on Phase 2 Findings
- ZymoGenetics Provides Update on rhThrombin Development Plans
- Thelin (sitaxentan sodium) Receives Australian Marketing Approval
- Authentix Partners with AstraZeneca to Protect Drug Supply with Unit-Level Mass Serialisation
- Avalon Pharmaceuticals and Merck & Co., Inc. Establish a Drug Discovery, Development and Commercialization Collaboration
- Litigation Settlement Reached Between Tercica, Genentech and Insmed
- Use of ADHD Medication Soars Worldwide
- CV Therapeutics Announces Topline MERLIN TIMI-36 Results
- AARP Presses Case for Rx Importation
- Pharmaceutical Company Ordered to Withdraw Advertising
- AARP Watchdog Report Shows Drug Prices Continue to Soar
- Lipitor Receives FDA Approval for Five New Indications in Patients With Heart Disease
- Acambis Restructures Organisation to Focus Resources on Key Programmes and Operations, and Reduce Cost Base by 20%
- Insmed Announces Restructure, Settlement Ending Iplex Patent Dispute
- Publicis Groupe Announces Acquistion of Pharmagistics (USA), Leader in Prescription Drug Compliance, Move Boosts PHCG's Technological and Digital Expertise
- African-American Doctors Say DTC Ads Improve Doctor-Patient Relationships and Educate Patients
March 8, 2007
- Algeta - Initial Public Offering
- Hollis-Eden Announces Cancellation of Acute Radiation Syndrome RFP by Department of Health and Human Services
- The Future of BioShield in Question?
- Message to Congress: Leave Canadian Prescription Drugs Alone
- OncoGenex Technologies Withdraws Initial Public Offering
- Nuvo Announces Further Update on Discussions With the FDA Related to Review of Pennsaid
- AARP Urges Congress to Pave Way for Generic Biologics
- Senior Scientist from Johnson & Johnson Testifies Before Senate HELP Committee on Follow-On Biologics
- Novartis Leads Learning Revolution in China
March 9, 2007
- Dorland Global Corporation Acquired by Huntsworth PLC
- Engel Publishing Partners Celebrates Its 25th Year as a Leading Pharmaceutical Information Provider
- U.S. Court of Appeals Reinstates Permanent Injunction Against Abbott Laboratories for Infringing Innogenetics' Patent
- IMS Health Reports U.S. Prescription Sales Jump 8.3 Percent in 2006, to $274.9 Billion
- FDA Sends Letter to Takeda Over Rozerem Advertisement
- Roche Files Supplemental New Drug Application with U.S. Food & Drug Administration for Tamiflu 30 mg and 45 mg Capsules
- PhRMA to Present Clinical Trial Exceptional Service Award
- Amgen Announces Update To U.S. Prescribing Information for Aranesp and Epogen
- Galen Partners and Arena Capital Partners Complete Sale of EduNeering Holdings, Inc., to Kaplan, Inc.
- Ortho Biotech Revises Prescribing Information for Procrit (Epoetin alfa)
March 12, 2007
- Takeda to Acquire Paradigm Therapeutics
- Schering-Plough to Acquire Organon BioSciences
- FDA Strengthens Safety Information for Erythropoiesis-Stimulating Agents (ESAs)
- Oxxon Therapeutics to be Acquired by Oxford Biomedica
- Entelos Trading Update
- Johnson & Johnson Receives Subpoenas
- Cangene Receives an Approvable Letter From the FDA for Human Growth Hormone
- Protherics to Receive £10 Million Milestone from AstraZeneca
- Avenue A / Razorfish Attributes Growth to Portals and Social Network Sites as its Online Advertising Spend Increases to $542 Million
- New European Approval for Xyrem Provides Significant Advance in the Treatment of Narcolepsy
March 13, 2007
- Sleeping Pill Advertisement Targeting Children Illustrates Need for Congress to Reform Prescription Drug Ads
- Allegra (fexofenadine hydrochloride) Oral Suspension Now Available to Help Manage Seasonal Allergy Symptoms In Children
- Merck & Co., Inc. to Appeal Humeston Vioxx Verdict
- Cellzome Receives First Milestone Payment for Alzheimer's Program from Ortho-McNeil Pharmaceutical, Inc.
- Baxter's Board of Directors Expands Share Repurchase Authorization By $2 Billion
- Pediatric Study Costs Rose Substantially from 2000 as Complexity Grew, According to Tufts Center for the Study of Drug Development
- Ecopia and Caprion Complete Combination and Announce Closing of $45 Million Private Placement: New Entity Called Thallion Pharmaceuticals Inc.
- Inflazyme Announces Outcome of Review of Phase 2b Asthma Study: Potential Mitigating Factors Identified which Prevent Clear Interpretation of Results
- FDA Approves Tykerb (lapatinib) in Combination With Xeloda (capecitabine) for the Treatment of Advanced or Metastatic Breast Cancer in Women Who Have Progressed on Prior Therapy
- Illumina Announces Outcome of First Phase of Its Patent Litigation against Affymetrix
March 14, 2007
- Cancer Drug, But Not Drug Company, Praised By Networks
- Neuromed Receives Milestone Payment of $2 Million Under Collaboration and License Agreement with Merck & Co., Inc.
- Baxter Holds 2007 Investor Conference in Chicago
- Bristol-Myers Squibb Significantly Expands Research And Development Presence In India Through Collaborations With Biocon And Accenture
- Study of Drug Therapy for Compulsive Buying Yields a Puzzle, Stanford Researcher Says
- Maxygen Announces End of Co-Development Agreement
- IR BioSciences, Inc. Responds to the Recently Cancelled Acute Radiation Syndrome (ARS) RFP by DHHS
- FDA Requests Label Change for All Sleep Disorder Drug Products
- Biopartners Holdings AG Purchased by Bioton S.A.
- Consona Corporation (M2M Holdings, Inc.) Closes on Acquisition of KNOVA Software, Inc.
- Eli Lilly and Company CEO Says Biomedical Breakthroughs Are Transforming Medicine and Promise to Radically Ease the Impact of Aging
March 15, 2007
- Synovics Pharmaceuticals Signs Letter of Intent to In-License OTC Generic Version of Omeprazole
- ALTANA 2006: Eleventh Record Year in Succession with Strong Growth in Sales and Earnings
- FDA Extends Marketing Exclusivity for Levaquin
- Eli Lilly Withdraws Its Marketing Authorization Application for Arxxant
- VaxGen Files Notice of Appeal Regarding Cancelled Anthrax Contract
- New Human Cell-Produced Treatment for Anaemia Associated with Chronic Kidney Disease Now Available
- 2006 a Record Year for Bayer
- Med Ad News’ March Issue Profiles 93 New Medicines Approved in 2006, Selects the Best New Medicine, and More
- Statement of Senator Edward M. Kennedy Hearing on Drug Safety and User Fees
March 16, 2007
- FDA Clears Rapid Test for Meningitis
- Tripos Shareholders Vote to Sell Discovery Informatics Business and Liquidate Company
- Trimeris and Roche Amend Research Agreement Covering Next-Generation HIV Fusion Inhibitors
- NeuroSearch Responds to Conclusions About Tesofensine Made by BiotekAnalyse Weekly
- Endo and Vernalis plc Announce Three-Month Extension of PDUFA Date for Frova sNDA
- CDC Releases Safety Data on Rotavirus Vaccine Reported Intussusception Cases Fall Within Expected Range
- FDA Approves Alexion's Soliris for All Patients With PNH
March 19, 2007
- Curecumin May Be an Effective Treatment for Prostate Cancer
- Coronary Artery Disease ARISE Trial Showed AGI-1067 Did Not Meet Primary Endpoint
- Update: FDA Approves Alexion's Soliris for All Patients With PNH
- Evotec and Boehringer Ingelheim Enter Into Target Discovery Collaboration in Alzheimer's Disease
- Medivir Receives Shares and Cash Payment from Epiphany Biosciences
- Social Networks Impact the Drugs Physicians Prescribe According to Stanford Business School Research
- Beijing Med-Pharm Corporation Signs Definitive Agreement for the Acquisition of Majority Interest in Shanghai Rongheng Pharmaceutical Co., Ltd.
- Auriga Laboratories Sales Force Doubles Again to 200 Associates Since January
- Shire Announces Expiration of Hart-Scott-Rodino Waiting Period
- AtheroGenics Reports ARISE Trial Results for AGI-1067
- Inyx Reports Update on Corporate Matters
- WellPoint Expands GenericSelect Program to Include Generic Version of Blockbuster Cholesterol-Lowering Treatment Zocor
- IMS Health Acquires ValueMedics Research in the U.S., Extending Capabilities to Demonstrate Value of Medicines
March 20, 2007
- Hold the Pickles and the Penicillin: Leading Food-Service Company to Serve Antibiotic-Free Hamburgers Nationwide
- Cetero Research Acquires Allied Research International, Gains Specialty Clinical Experience
- InterMune Updates Expense Forecasts and Development Plans
- 3SBio Inc. Announces Addition to Product Portfolio
- Astellas Receives and FDA Action Letter for Prograf sNDA
- Takeda's New Structure for Pharmaceutical Marketing Division in Japan
- Takeda Submits a European Marketing Authorization Application for Ramelteon, a New Treatment for Insomnia
- Corcept Therapeutics Announces Phase 3 Study Evaluating Corlux for Psychotic Major Depression Misses Primary Endpoint
- Medical Discoveries Inc. Engages Strategic Advisor to Explore Alternatives
- Taro Files 2005 Form 20-F Following Completion of 2005 Audit
- Barr Confirms Filing an Application with a Paragraph IV Certification for Abilify Tablets
- New Data from the US and Japan Support: No Established Causal Link Between Neuropsychiatric Symptoms and Treatment with Tamiflu US Databases Indicate Psychiatric Symptoms Lower in Influenza Patients Taking Tamiflu Versus Those Not Taking Tamiflu
- New Cancer Practice Guidelines Recommend Noxafil (Posaconazole) for Antifungal Prophylaxis in Certain High-Risk Patients
- New Treatment Option for Epilepsy Patients With One of the Most Debilitating Seizure Types
- Pfizer Wins Celebrex Patent Challenge by Generic Manufacturer Teva
March 21, 2007
- Merck Initiates Squeeze Out Procedure for Shares of Merck Serono S.A.
- AstraZeneca Inaugurates State-of-the-Art Global Process R&D lab in Bangalore
- IMS Health Reports Global Pharmaceutical Market Grew 7.0 Percent in 2006, to $643 Billion
- Tripos Completes Sale of Discovery Informatics Business to Vector Capital Corporation
- PhRMA Statement on JAMA Article
- Disclosure Laws Provide Only Limited View of Pharmaceutical Company Payments to Physicians
- Teva Provides Update on Generic Celebrex Litigation
- Adderall XR - Shire Files Suit Against Colony Pharmaceuticals, Inc., Actavis, Inc. and Actavis Group hf
- FDA Proposes New, Tougher Procedures for Membership on Advisory Committees
March 22, 2007
- Conceivex At-Home Conception Kit Puts Couples in Control of Their Fertility
- Eisai To Acquire Morphotek
- Dey, L.P. Reaches Settlement with State of Hawaii on Pricing Litigation
- Cubist Pharmaceuticals Licenses Rights for Development and Commercialization of Cubicin in Japan to Merck & Co., Inc.
- PDI, Inc. Comments on Status of a Substantial Contract Sales Program
- Reps. Dingell, Stupak Call on Amgen, Johnson & Johnson to Suspend Direct-to-Consumer Marketing for Anemia Drugs
- Bayer Schering Pharma Presents Innovations in Men's Healthcare at the 22nd Annual Meeting of the European Association of Urology (EAU)
- U.S. District Court Grants Permanent Injunction Prohibiting Mylan from Marketing Generic Version of Topamax
- Acomplia (rimonabant) is Now Officially Reimbursable in France, for the Treatment of Eligible Obese and Type 2 Diabetic Patients
- GSK Announces Nationwide Availability of Once-A-Day Coreg CR for the Treatment of Three Key Cardiovascular Conditions
- GSK Giving Figures Exceed £300m for Fourth Year Running: Medicines for Lymphatic Filariasis Elimination Valued at £16 Million
- Pharmacist, Patient Groups Call for Inquest into B.C. Counterfeit-Pills Death
- VASTox plc Acquires DanioLabs Ltd and Dextra Laboratories Ltd to Strengthen Its Drug Discovery Pipeline and Pharmaceutical Services Business
- PEDIATRIC DRUG RESEARCH:Studies Conducted under Best Pharmaceuticals for Children Act
- DRUGSAFETY: FDA Needs to Further Address Shortcomings in Its Postmarket Decision-making Process
March 23, 2007
- AstraZeneca Names Shanghai Site As Initial Base for New Innovation Centre China
- NovaDel's European Formulation of Ondansetron Targeted for U.S. Zensana
- CDC Finalizes Advisory Panel Recommendations for Gardasil, Merck's Cervical Cancer Vaccine
- Amgen Discontinues Vectibix Treatment in PACCE Trial Evaluating Vectibix as Part of Triple Combination Regimen
- Hana Biosciences Provides Pipeline Update
- Sen. Durbin Amendment to Delay Potential Cuts in Medicaid Payments to Hospitals Nationwide Successfully Addded to Supplemental Spending Bill
- Procognia Enters Protein Kinase Array Collaboration With GSK
- Pfizer Statement in Response to Appeals Court Decision in Norvasc Patent Case
- Pozen Announces Trexima (Sumatriptan Succinate and Naproxen Sodium) Amended Response Accepted for Review by FDA
- Leukemic Cells Find Safe Haven in Bone Marrow
- Marketing Authorisation Application for Ambrisentan Validated by European Medicines Agency
- Genentech to Provide Business Update at Annual Investment Community Meeting
- UCB Provides Update on Cimzia for Crohn's Disease and Rheumatoid Arthritis in the US
- Flamel Technologies Welcomes Nationwide Availability of Coreg CR
- Dalton Medicinal Chemistry Partners and Boehringer Ingelheim (Canada) Ltd. enter into a Medicinal Chemistry Agreement
- European Medicines Agency Statement on Safety of Tamiflu
- Avicena Clarifies Description of Creatine Versus PD-02, Company's Lead Drug Compound Used in NIH Phase III Clinical Trial in Parkinson's Disease
- Mylan Laboratories Launches Amlodipine Besylate Tablets and Has Triggered Its 180 Days of Exclusivity
- Advancis Pharmaceutical Resubmits New Drug Application for Once-Daily Amoxicillin PULSYS
March 26, 2007
- Mylan Announces Another First to Market With the Launch of Ciprofloxacin Extended-Release Tablets
- Arrowhead to Form New Nanomedicine Subsidiary and Acquire Nanotherapeutics Company, C Sixty, Inc.
- First Study To Show Positive Benefit On Atherosclerosis For People With Early Signs Of Diseased Arteries
- Abbott Announces Positive Six-Month Results From the World's First Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent
- Bayer Deal with Novartis Improves Profit Outlook for Betaseron Franchise
- Abbott's Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
- Novartis to Launch Its Own Branded Version of a Leading Multiple Sclerosis Therapy Through Agreement with Bayer Schering Pharma
- Insmed Withdraws Its Marketing Authorisation Application for Iplex
- Genta Announces Expectation of a Negative Opinion from the CHMP on Genasense Application for Advanced Melanoma
- Januvia Approved in the European Union for the Treatment of Type 2 Diabetes
- Asahi Kasei Pharma Corporation and Eisai Co., Ltd. Signed License Agreement for Vasodilator Eril in Korea
- Schering-Plough and Merck to Develop Another New Cholesterol Lowering Medicine
- Herceptin Receives Positive Opinion in Europe for Use in Combination with an Aromatase Inhibitor for the Treatment of Patients with Her2- and Hormone Receptor-positive Metastatic Breast Cancer
- Scios Announces Results From Exploratory Nesiritide Study Providing Important New Renal and Mortality Safety Data with a Neutral Effect on the Primary Endpoint
- Everest Data on Short- and Long-Term Use of Otsuka's Investigational Novel Treatment, Tolvaptan, Published in Journal of the American Medical Association and Featured in ACC's Late Breaking Clinical Trials
- Cholesterol Drug Fails to Slow Progression of Coronary Disease, Cleveland Clinic Study Reports
- Wyeth Receives FDA Approval for New BeneFIX Features That Provide Hemophilia B Patients a Simpler and More Convenient Preparation Process for Recombinant Factor IX
- Shire Announces Posting of Circular, Date of Extraordinary General Meeting and Extension of Tender Offer for New River Shares Until April 17, 2007
- Study: Identical Doses of BiDil Components Are Not Bioequivalent to the Fixed Dose Combination-BiDil-Used in A-HeFT
- Roche Submits Application to the FDA for use of Xelox (Xeloda plus oxaliplatin) With or Without Avastin for the Treatment of Advanced Colorectal Cancer
- EvoGenix Achieves Milestone in Collaboration with GlaxoSmithKline
- European Union CHMP Recommends Approval of First and Only Biologic Treatment for Pediatric Crohn's Disease: Remicade
March 27, 2007
- U.S. District Court Enjoins the FDA from Approving Additional Amlodipine Besylate ANDAs
- Replidyne Defines Preliminary Phase III Development Plan for Faropenem
- BioCryst Provides Fodosine Update
- Acuity Pharmaceuticals and Froptix Corporation Agree to Mergers with Public Shell; New Company to Develop and Market Drugs for Disorders of the Eye
- BrainCells and Lundbeck Form CNS Drug Research Collaboration
- FDA MedWatch-KETEK telithromycin) Dear Healthcare Professional letter issued re: safety related labeling changes
- Lipitor Provides Unprecedented Cardiovascular Risk Reductions in Diabetes Patients with Metabolic Syndrome and in Stroke Patients
- Boehringer Ingelheim Grows Faster Than the Market Once Again - Spiriva, Micardis and Flomax/Alna the Top Products
- Seattle Genetics Announces Extension of Antibody-Drug Conjugate Collaboration with Genentech
- NICE Alzheimer's Treatment Decision Subject to Judicial Review
- Heart Intervention Doesn’t Outweigh Medicine in Study
- Merck Wins Product Liability Case in Madison County, Ill. - Schwaller v. Merck
- Lipitor Significantly Lowered Hospitalization Costs for Patients with Heart Disease, Two New Analyses Show
March 28, 2007
- Pharmacopeia Earns Milestone Payment From Schering-Plough As Novel Therapeutic Candidate Enters Phase 1 Clinical Trial
- Sanofi-aventis and Oxford BioMedica Enter Global Licensing Agreement to Develop and Commercialise TroVax For Cancer
- Cell Signaling Technology Announces Alliance with Merck to Provide PhosphoScan Proteomics & Antibody Development for Biomarker Discovery to Support Oncology Therapeutic Programs
- Calcium Channel Blocker Adalat GITS Offer Additional Benefits
- CSL Therapy That Mimics “Good” Cholesterol May Reduce Plaque Volume in Coronary Arteries
- Merck & Co., Inc. and Lundbeck Discontinue Joint Development Program for Gaboxadol, an Investigational Compound for Insomnia
- Daiichi Sankyo, Inc. Announces Filing For WelChol Label Change to Include Ezetimibe Efficacy Data
- Clinical Development Initiated on Lead Compound in NicOx’ Glaucoma Collaboration with Pfizer
- MorphoSys and Astellas Enter Antibody Partnership
- Beijing Med-Pharm Corporation Signs Definitive Agreement for the Acquisition of Majority Interest in Shanghai Rongheng Pharmaceutical Co., Ltd.
- FDA MedWatch: Accutane (isotretinoin)- Webpage Warning Against Buying Product and Generic Versions On Line
March 29, 2007
- VWR International, Inc. Acquires Remaining Stake in KMF Laborchemie Handels GmbH
- NicOx Announces that Pfizer has Disclosed Further Details of Glaucoma Trial for PF-03187207
- CuraGen Announces Definitive Agreement to Sell 454 Life Sciences to Roche
- Avastin Approved in Europe for First Line Treatment of Women with Metastatic Breast Cancer
- KV Pharmaceutical Updates Metoprolol Succinate Application Status
- Ad hoc Release According to Section 15 WpHG
- Cytori To Raise $6.0 Million in Strategic Equity Agreement with Green Hospital Supply
- NeoPharm Reports on FDA Meeting
- Avanir Pharmaceuticals Provides Business Update and Announces Restructuring Plan
- Roche Acquires 454 Life Sciences to Strengthen Presence in Ultra-Fast Gene Sequencing
- R&D Directions’ March Issue Profiles 100 Great Investigational Drugs, Talks with Pfizer’s President of Global Research & Development, and More
- MedImmune Licenses Reverse Genetics Technology to sanofi pasteur for Use in Influenza Vaccine Production
- Study Sheds Light on Medication Treatment Options for Bipolar Disorder
- Athersys Successfully Advancing Multiple Commercial Collaborations
- GlaxoSmithKline Submits Biologics License Application to U.S. Food and Drug Administration for Cervarix
March 30, 2007
- GlaxoSmithKline Files Meningococcal Conjugate Vaccine
- Progenics and Wyeth Announce Submission of New Drug Application for the Subcutaneous Formulation of Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients Receiving Palliative Care
- Astellas Licenses Regeneron's Velocimmune Technology for Discovering Human Monoclonal Antibodies
- FDA Announces Voluntary Withdrawal of Pergolide Products
- Dendreon Announces FDA Advisory Committee Reviewed Provenge for Hormone Refractory Prostate Cancer
- Xeloda Approved in Europe for the Treatment of Advanced Stomach Cancer
- European Medicines Agency Recommends Restricted Use and Strengthened Warnings for Ketek
- CanBas and Takeda to Sign the Collaboration Agreement for Investigational Compounds for Treatment of Cancer
- LG Life Sciences and Takeda Announce Collaboration for Anti-Obesity Drugs
- Takeda to Obtain Development and Commercial Rights for R-851 from 3M
- Galapagos Announces Achievement of Milestones Totaling €3.2 Million in Osteoarthritis Alliance with GlaxoSmithKline
- Completion of the Acquisition of CellCyte Genetics Corporation (WA)
- Novartis Suspends US Marketing and Sales of Zelnorm In Response to Request from FDA
- New Chemistry Approach Promises Less Expensive Drugs
- Amicus Therapeutics Files For Initial Public Offering
